The Lynx Group

Robert E. Henry


Authored Items

Preserving Personalized Medicine – Holding Fast to Healthcare’s Governing Dynamics

December 2013, Vol 2, No 8 - The Last Word

What do we say at the end of this contentious year in healthcare, when government, the least of healthcare’s 3 siblings – clinical, business, and government – pushed its brethren aside and demanded to lead the parade? To be certain, the “dynamic tension” between our healthcare’s sectors historically has been [ Read More ]

To PARP or Not to PARP – What Is the Question? Part 2 Perspective on the First “Disappointment” With a New Drug Class

November 2013, Vol 2, No 7 - The Last Word

In the first article on this topic, appearing in the last issue of PMO, we looked at a sequence of events surrounding an attempt to achieve quick consensus concerning the treatment of metastatic triple-negative breast cancer (TNBC) with a PARP inhibitor. O’Shaughnessy et al selected iniparib as the PARP inhibitor [ Read More ]

Immunotherapy in Cancer Care: Personalized or Population-Based Medicine…and the Janusian Factor

August 2013, Vol 2, No 5 - The Last Word

Is immunotherapy a type of personalized medicine (PM) or just useful population-based medicine? Look in different directions and you’ll get different answers, but whatever we do, let’s avoid oversimplification. For when we get down to specifics, the accurate answer is, “It depends.” When in doubt, it is often useful to [ Read More ]

The Affordable Care Act and Oncology Personalized Medicine: Compatibility and the Governing Dynamics of Healthcare

April 2013, Vol 2, No 2 - The Last Word

Our last column examined the tripartite nature of healthcare: a clinical/business/policy entity with each of the 3 sectors influencing the net condition of healthcare. While the healthcare entity should act in balance, in reality each sector periodically springs forward with powerful initiatives and “takes charge” of healthcare until another sector [ Read More ]

Personalized Medicine in Oncology: The Landscape of the Next Generation of Cancer Care

May 2012, Vol 1, No 1 - Uncategorized

Personalized medicine. Innovation’s 21st century poster child … and bastion of medical uncertainty, wishful thinking, and unfulfilled aspirations striking terror into the ledger sheets of payers unable to cope with conventional (empirical) medicine. Mastering personalized medicine (PM) requires an awareness of its governing dynamics, understanding that it exists in many [ Read More ]

Sign me up!